Kröll, Dino; Nett, Philipp C.; Rommers, Nikki; Borbély, Yves; Deichsel, Fabian; Nocito, Antonio; Zehetner, Jörg; Kessler, Ulf; Fringeli, Yannick; Alberio, Lorenzo; Candinas, Daniel; Stirnimann, Guido (2023). Efficacy and Safety of Rivaroxaban for Postoperative Thromboprophylaxis in Patients After Bariatric Surgery: A Randomized Clinical Trial. JAMA network open, 6(5), e2315241. American Medical Association 10.1001/jamanetworkopen.2023.15241
|
Text
krll_2023_oi_230469_1684266831.50671.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (993kB) | Preview |
IMPORTANCE
Venous thromboembolism (VTE) is a leading cause of morbidity and mortality after bariatric surgery. Clinical end point studies on thromboprophylaxis with direct oral anticoagulants in patients undergoing bariatric surgery are lacking.
OBJECTIVE
To assess the efficacy and safety of a prophylactic dose of 10 mg/d of rivaroxaban for both 7 and 28 days after bariatric surgery.
DESIGN, SETTING, AND PARTICIPANTS
This assessor-blinded, phase 2, multicenter randomized clinical trial was conducted from July 1, 2018, through June 30, 2021, with participants from 3 academic and nonacademic hospitals in Switzerland.
INTERVENTION
Patients were randomized 1 day after bariatric surgery to 10 mg of oral rivaroxaban for either 7 days (short prophylaxis) or 28 days (long prophylaxis).
MAIN OUTCOMES AND MEASURES
The primary efficacy outcome was the composite of deep vein thrombosis (symptomatic or asymptomatic) and pulmonary embolism within 28 days after bariatric surgery. Main safety outcomes included major bleeding, clinically relevant nonmajor bleeding, and mortality.
RESULTS
Of 300 patients, 272 (mean [SD] age, 40.0 [12.1] years; 216 women [80.3%]; mean body mass index, 42.2) were randomized; 134 received a 7-day and 135 a 28-day VTE prophylaxis course with rivaroxaban. Only 1 thromboembolic event (0.4%) occurred (asymptomatic thrombosis in a patient undergoing sleeve gastrectomy with extended prophylaxis). Major or clinically relevant nonmajor bleeding events were observed in 5 patients (1.9%): 2 in the short prophylaxis group and 3 in the long prophylaxis group. Clinically nonsignificant bleeding events were observed in 10 patients (3.7%): 3 in the short prophylaxis arm and 7 in the long prophylaxis arm.
CONCLUSIONS AND RELEVANCE
In this randomized clinical trial, once-daily VTE prophylaxis with 10 mg of rivaroxaban was effective and safe in the early postoperative phase after bariatric surgery in both the short and long prophylaxis groups.
TRIAL REGISTRATION
ClinicalTrials.gov Identifier: NCT03522259.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology 04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine 04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Visceral Surgery |
UniBE Contributor: |
Kröll, Dino, Nett, Philipp C., Borbély, Yves Michael, Candinas, Daniel, Stirnimann, Guido |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2574-3805 |
Publisher: |
American Medical Association |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
26 May 2023 16:17 |
Last Modified: |
26 May 2023 16:26 |
Publisher DOI: |
10.1001/jamanetworkopen.2023.15241 |
PubMed ID: |
37227726 |
BORIS DOI: |
10.48350/182934 |
URI: |
https://boris.unibe.ch/id/eprint/182934 |
Actions (login required)
 |
Edit item |